EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism

Irene Tizianel, Alberto Madinelli, Filippo Crimì, Mattia Barbot, Simona Censi, Chiara Sabbadin, Filippo Ceccato

Clinical Endocrinology · 2025

DOI: 10.1111/cen.15231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Irene Tizianel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine DIMED, Endocrine Unit, Padua, Italy. Hauptthemen laut MEDLINE: Hyperaldosteronism, Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the prevalence of metabolic associated steatotic liver disease (MASLD) in patients with primary aldosteronism (PA) compared to benign adrenal adenomas, and to evaluate the impact of hormonal excess in inducing MASLD.

Design

Single‐centre retrospective study.

Methods

Hepatic steatosis was assessed by liver/spleen (L/S) ratio from unenhanced abdomen computed tomography images (reference value < 1.1) in a cohort of 41 patients with PA without cortisol cosecretion, 20 unilateral (uPA) and 21 bilateral (BPA), 50 with nonfunctioning adrenal incidentalomas (NF‐AI), 48 with mild autonomous cortisol secretion (MACS) and 10 with adrenal Cushing Syndrome (CS).

Results

Hepatic steatosis was increased in patients with PA at diagnosis: L/S ratio was lower in PA than NF‐AI (1.1 vs. 1.25, p < 0.001) and MACS (1.1 vs. 1.21, p 0.007), but was similar to adrenal CS (1.1 vs. 1.15, p = 0.147). A improvement in L/S ratio after medical or surgical treatment was observed in PA patients, resulting in reduced liver steatosis. MASLD prevalence was higher in PA compared to MACS (49% vs. 25%, p < 0.05) and NF‐AI (49% vs. 14%, p < 0.001), but similar to CS (49% vs. 45%, p = 0.61). uPA patients had higher MASLD prevalence compared to BPA group 71% (53%–89%) versus 25% (7%–43%).

Conclusions

Prevalence of MASLD was increased in PA (higher in uPA than BPA) compared to MACS and NFAI, and similar to adrenal CS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperaldosteronismFatty LiverHumansMaleFemaleMiddle AgedRetrospective StudiesPrevalenceAdultAgedHydrocortisoneAdrenal Gland Neoplasms

Stichwörter der Autor:innen

adrenal incidentalomacomputed tomographymetabolic associated steatotic liver diseasemild autonomous cortisol secretionprimary aldosteronism

Substanzen

Hydrocortisone

Autor:innen und Institutionen

  • Department of Medicine DIMED, Endocrine Unit, Padua, Italy.
  • Endocrine Unit, University-Hospital of Padova, Padua, Italy.
  • Institute of Radiology, University-Hospital of Padova, Padua, Italy.

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Tizianel, I., Madinelli, A., Crimì, F., Barbot, M., Censi, S., Sabbadin, C., & Ceccato, F. (2025). Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism. Clinical Endocrinology. https://doi.org/10.1111/cen.15231

Vancouver

Tizianel I, Madinelli A, Crimì F, Barbot M, Censi S, Sabbadin C, et al. Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism. Clinical Endocrinology. 2025. doi:10.1111/cen.15231

BibTeX
@article{Tizianel2025,
  author = {Tizianel, Irene and Madinelli, Alberto and Crimì, Filippo and Barbot, Mattia and Censi, Simona and Sabbadin, Chiara and Ceccato, Filippo},
  title = {Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism},
  journal = {Clinical Endocrinology},
  year = {2025},
  doi = {10.1111/cen.15231}
}
Kostenlos starten →